February 2011

Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.

December 2012

Tokyo office was opened in Chiyoda-ku, Tokyo.

September 2013

Business name was changed to HEALIOS K.K.
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.

October 2013

Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.

December 2013

Agreement signed with Sumitomo Dainippon Pharma Co., Ltd. (Current: Sumitomo Pharma Co., Ltd.) on the joint development in Japan of iPS cell–derived RPE cells for the treatment of age-related macular degeneration. A patent licensing agreement and a joint venture contract was also signed.
Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.

February 2014

Sighregen Co.,Ltd., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., (Current: Sumitomo Pharma Co., Ltd.) was established.

September 2014

Main office was moved to Minato-ku, Tokyo.

October 2014

Start of collaborative research with Yokohama City University on cellular and tissue-based products using iPS and other cells.

June 2015

Listed on the Tokyo Stock Exchange market Mothers (code: 4593).

January 2016

A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.

February 2017

A business and capital alliance agreement signed with Nikon Corporation in the field of regenerative medicine.

April 2017

Ophthalmic viscoelastic preparation business containing BBG250 was transferred to D. Western Therapeutics Institute, Inc.

February 2018

Establishment of Healios NA, Inc. in USA

June 2019

Change in joint development framework with Sumitomo Dainippon Pharma (Current: Sumitomo Pharma Co., Ltd.) in Japan for the treatment using iPSC-derived RPE cells.

July 2019

Expansion of business and capital alliance with Nikon in the field of regenerative medicine.

January 2020

Adoption of International Financial Reporting Standards (IFRS)

October 2020

Main office was moved to Chiyoda-ku, Tokyo.

January 2021

Establish ment of fund subsidiaries in the field of regenerative medicine. including Saisei Ventures LLC in the U.S.

August 2021

Sign of an agreement with Athersys to expand the overall scope of collaboration for commercialization.

April 2022

Moved to the Tokyo Stock Exchange Growth Market due to a revision of the market classification.

July 2023

Establishment of subsidiary ProcellCure, Inc.

August 2023

Establishment of subsidiary eNK Therapeutics, Inc.

October 2023

Obtained a global license from Athersys, Inc. for MultiStem® for the treatment of acute respiratory distress syndrome (ARDS).

April 2024

Acquisition of substantially all of the assets of Athersys, Inc